Week 9 DM / Thyroid Flashcards
Glyburide
Class
Sulfonylureas
DM
Glipizide
Class
Sulfonylureas
DM
Sulfonylureas
MOA
increases endogenous insulin secretion by beta cells by closing ATP/K channels
Sulfonylureas
SE
weight gain, hyperinsulinemia, nausea, epigastric fullness, heartburn, diarrhea, rash, SAIDH (esp CHF and cirrhosis pt), dizzy, nervousness, tremor
Pioglitazone (Actos)
Classs
Thiazolidinediones
DM
Rosiglitazone (Avandia)
Class
Thiazolidinediones
DM
TZDs
MOA
selecive activators of peroxisome proliferator-activated receptor gamma leads to increased use of available insulin by liver and muscle cells, reduces hepatic glucose production
TZD
Black Box Warning
new CHF, vasodilation causes sodium retention –>fluid retention inc extracellular fluid
TZD
ADR
signs CHF, cardiac ischemia, hepatic dysfunction, need increase oral contraceptive or alternative
TZD
Monitor
LFTs
A1C
Acarbose
Class
Alpha-glucosidase inhibitors
DM
Miglitol
Class
alpha-glucosidase inhibitor
DM
Alpha-Glucosidase Inhibitor
MOA
inhibit enzyme from breaking down complex carbs in small intestine, delaying digestion to move further down bowel
Alpha-Glucosidase Inhibitor
Contraindication
IBS, risk bowel obstruction, colonic ulceration, chronic intestinal disease,
do not take with charcoal or digestive enzyme or pancreatic enzymes
Not for renal impairment
Repaglinide (Prandin)
Class
Meglitinides
DM
Nateglinide
Class
Meglitinides
DM
Meglitinides
MOA
closes ATP/K channels in beta cells membrane leading to opening Ca channels to increase Ca which leads to inc insulin/ promotes insulin secretion
Meglitinides
Caution
renal impairment and hepatic impairment
Selective Sodium Glucose Co-Transporter 2 (SGLT-2)
MOA
blocks enzyme to block reabsorption of glucose in kidneys so it can be excreted in the urine